Cardinal Health Sees IRA Pricing Changes as Fiscal 2027 Pharma Revenue Headwind

RegulationEarnings
โดย Zacks Investment Research·US·Read original
Summary · why it matters

Cardinal Health expects the annualization of 2026 Inflation Reduction Act price changes and the implementation of 2027 changes to create a revenue headwind for its Pharma business in fiscal 2027 comparable to the roughly 500-basis-point hit it took in the fourth quarter, though management expects no adverse profit impact. In the fourth quarter, IRA-related WACC changes represented an approximately 500-basis-point headwind to Pharma revenues, roughly offsetting a similarly sized GLP-1 tailwind. Management said the company aims to keep being compensated for the services it provides rather than absorbing the economics of regulatory changes, and pointed to the durability of its core distribution business, a major GMPD renewal and an extended Kroger relationship as sources of commercial stability. Among peers, BrightSpring Health Services expects the IRA to cut Home and Community Pharmacy revenues by approximately $200 million in 2026, or about $50 million per quarter, with an estimated EBITDA impact of only $15 million for the full year, while in Specialty and Infusion it sees roughly $175 million of revenue pressure and essentially no EBITDA impact. CVS Health did not separately quantify the IRA's specific margin impact, but said Pharmacy & Consumer Wellness revenues were pressured by regulatory-related price reductions on certain drugs, generic introductions and reimbursement pressure, even as adjusted operating income rose more than 10% year over year. Cardinal Health shares have gained 13.2% so far this year, and the Zacks Consensus Estimate for its fiscal 2027 earnings implies an 11.5% rise from the year-ago reported number.

Impact on stocks 3

Health Care▼ · 2 stocks
Cardinal Health Inc
CAH
▼ NegativeRegulationrelevance

Cardinal Health expects annualized 2026 and new 2027 IRA price changes to create a ~500bp Pharma revenue headwind in fiscal 2027, though with no adverse profit impact.

CVS Health Corp
CVS
▼ NegativeRegulationrelevance

CVS said Pharmacy & Consumer Wellness revenues were pressured by regulatory-related price reductions on certain drugs, alongside generic introductions and reimbursement pressure.

Aging Population▼ · 1 stocks
© 2026 MarketDXNews